Amgen Inc. $AMGN Shares Purchased by Smith Chas P & Associates PA Cpas

Smith Chas P & Associates PA Cpas lifted its position in Amgen Inc. (NASDAQ:AMGN) by 70.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 118,287 shares of the medical research company’s stock after purchasing an additional 49,013 shares during the quarter. Amgen makes up 2.0% of Smith Chas P & Associates PA Cpas’ investment portfolio, making the stock its 21st biggest holding. Smith Chas P & Associates PA Cpas’ holdings in Amgen were worth $38,716,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Dogwood Wealth Management LLC boosted its position in shares of Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 55 shares during the period. Anfield Capital Management LLC boosted its position in shares of Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 70 shares during the period. Board of the Pension Protection Fund acquired a new stake in shares of Amgen in the 4th quarter valued at about $26,000. Manning & Napier Advisors LLC boosted its position in shares of Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 32 shares during the period. Finally, Olistico Wealth LLC acquired a new stake in shares of Amgen in the 4th quarter valued at about $33,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have weighed in on AMGN. Jefferies Financial Group began coverage on Amgen in a research report on Tuesday, March 10th. They set a “hold” rating and a $350.00 price objective for the company. The Goldman Sachs Group increased their price objective on Amgen from $415.00 to $425.00 and gave the stock a “buy” rating in a research report on Friday, May 1st. Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a research report on Saturday, May 23rd. Erste Group Bank reaffirmed a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. Finally, Freedom Capital raised Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $355.19.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.85% of the company’s stock.

Amgen Stock Up 0.0%

Amgen stock opened at $336.06 on Thursday. Amgen Inc. has a twelve month low of $267.83 and a twelve month high of $391.29. The stock has a 50 day moving average of $343.32 and a two-hundred day moving average of $345.27. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The stock has a market capitalization of $181.37 billion, a price-to-earnings ratio of 23.39, a PEG ratio of 3.37 and a beta of 0.44.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the prior year, the business posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, research analysts expect that Amgen Inc. will post 22.37 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio is 70.15%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.